1 – Quoted prices in active markets for identical assets and liabilities.
2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar
assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated
by observable market data for substantially the full term of the assets or liabilities.
3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.
determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use
of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For
the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for
cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held
by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.
carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates,
accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these
carrying amount of the Loan Payable to Silicon Valley Bank approximates fair value because the loan bears interest at a floating
market rate (see Note 5).
and cash equivalents
equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December
31, 2017 and 2016, OncoCyte’s cash balances totaled $7.6 million and $10.2 million, respectively.
instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains
cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies.
OncoCyte places its cash and cash equivalents with high credit quality financial institutions.
for BioTime shares
accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25, Investments
– Debt and Equity Securities, as the shares have a readily determinable fair value quoted on the NYSE American and are
held principally for future working capital purposes, as necessary. These shares are measured at fair value and reported as current
assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding
gains and losses are excluded from the statements of operations and reported in equity as part of other comprehensive income or
loss, net of income taxes, until realized. As discussed in Note 1, on February 17, 2017, BioTime deconsolidated OncoCyte’s
financial statements from its consolidated financial statements. Due to this deconsolidation, and based on BioTime no longer having
“control” over OncoCyte under GAAP, any realized gains and losses OncoCyte generates from the sale of BioTime shares
after February 17, 2017 are included in the statements of operations. Prior to February 17, 2017, any realized gains and losses
for shares sold were reclassified out of accumulated other comprehensive income or loss and included in equity, as an increase
or decrease to common stock equity consistent with, and pursuant to, ASC 805-50 Business Combinations (“ASC 805”),
transactions between entities under common control. See section Recent Accounting Pronouncements included herein.
2017, OncoCyte sold 266,442 shares of BioTime common stock for net proceeds of $934,000 and recognized a $309,000 loss from the
sale of the BioTime shares included in other income and expenses, net. The proceeds were used to pay down amounts owed to BioTime
and affiliates (see Note 4). No shares of BioTime common stock were sold in 2016. In 2015, OncoCyte sold 259,712 shares of BioTime
common stock it held in at-the-market transactions for $815,000 in net cash proceeds to be used for working capital purposes.
The sale resulted in a $397,000 realized loss, which is recorded as a decrease to common stock equity on the dates of sale.
of December 31, 2017, OncoCyte held 353,264 BioTime common shares as available-for-sale securities with a fair market value of
$0.8 million. Any proceeds from the sale of BioTime shares may be used by OncoCyte to pay amounts owed to BioTime and its affiliates
or for working capital purposes.
intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated
at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method
over the estimated useful lives of the assets over a period of 10 years.